Background: In the US and Europe, lymphoma incidence fell with introduction of ART. However, incidence of non-Hodgkin’s (NHL) and Hodgkin’s lymphoma (HL) has risen despite excellent ART access in Botswana. We sought to better understand the paradoxical rise in incidence and assess the treatment and outcomes of patients with NHL and HL in Botswana.
Methods: We enrolled all consenting adults treated for lymphoma between 10/2010 and 9/2014 at two referral hospitals in Gaborone, Botswana. Standard treatment included 6 cycles of CHOP (recently with rituximab) for NHL and 6 cycles of ABVD for HL. ART-naïve HIV-infected patients or those who started ART within 6 months of lymphoma diagnosis were categorized as off ART. Exact methods were used for categorical measures and survival was assessed using Cox modeling adjusted for lymphoma type (NHL or HD).
Results: Seventy-two patients were enrolled (56 NHL, 16 HL) and followed for a median 12.9 months. Fifty-two (72%) patients were HIV-infected and 20 (28%) were HIV-uninfected. The median age of HIV-infected and HIV-uninfected patients was 37 and 52 years with NHL (P=0.059) and 40 and 32 years with HL (P=0.38), respectively. Among HIV-infected, 42% of lymphomas were diagnosed in patients on ART (median duration 2.6 years), with median CD4 count of 255 cells/µL (IQR 147-390 cells/µL) for NHL and 401 cells/µL (IQR 311-525 cells/µL) for HL. In those patients off ART, 41% were eligible to have been initiated on ART by CD4 count alone (≤ 250 cells/µL). Fifty percent of NHL and 36% of HL patients presented at advanced stages (Ann Arbor stage III or IV). Chemotherapy records were analyzed in 43 (60%) cases and all patients were started on standard treatment regimens. Treatment modifications were common and due to toxicity (22 instances) and chemotherapy stock out (5 instances). Sixteen NHL patients (28%) and 1 HL patient (6%) died during follow-up. The one-year survival was 74% (95% CI 58 – 84%) for NHL and 93% (95% CI 59-99%) for HL. While power was low, no significant differences were detected in stage at presentation (p=0.76), treatment modification (p=0.60), or survival (HR 0.76, 95% CI 0.26-2.2) by HIV status.
Conclusions: Despite ART coverage exceeding 90% by government estimates, the majority of lymphomas were diagnosed in patients off ART with relatively high CD4 cell counts. Persistently high incidence may be related to low CD4 thresholds for ART eligibility. HIV-infection was not associated with reduced survival, although sample size was limited.